Antibody Responses after COVID-19 Infection in Patients Who Are Mildly Symptomatic or Asymptomatic in Bangladesh

Shirin, Tahmina; Bhuiyan, Taufiqur Rahman; Charles, Richelle C.; Amin, Shaheena; Bhuiyan, Imran; Kawser, Zannat; Rahat, Asifuzaman; Alam, Ahmed Nawsher; Sultana, Sharmin; Aleem, Abdul; Khan, Manjur Hossain; Khan, Samsad Rabbani; LaRocque, Regina C.; Calderwood, Stephen B.; Ryan, Edward T.; Slater, Damien; Clemens, John D.; Harris, Jason B.; Flora, Meerjady Sabrina; Qadri, Firdausi

doi:10.2139/ssrn.3675451

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings differ from western reports that showed much higher seroconversion among asymptomatic individuals [12–14]. However, a recent study from Bangladesh has reported lower seroconversion rates (45%) among asymptomatic individuals [15]. This raises the possibility that the biological responses to SARS COV-2 may vary between different populations.…”

Section: Discussioncontrasting

confidence: 99%

Longitudinal serology in SARS-CoV-2 infected individuals in India – a prospective cohort study

Thiruvengadam

Chattopadhyay

Mehdi

et al. 2021

Preprint

View full text Add to dashboard Cite

Clinical and epidemiological characteristics of SARS-CoV-2 infection are now widely available, but there are little data on longitudinal serology in large cohorts, particularly from low-and middle-income countries. We established an ongoing prospective cohort of 3840 SARS-CoV-2 RT-PCR positive individuals in the Delhi-National Capital Region of India, to document clinical and immunological characteristics during illness and convalescence. The IgG responses to the receptor-binding domain (RBD) and nucleocapsid were assessed at 0-7, 10-28 days, and 6-10 weeks after infection. The clinical predictors of seroconversion were identified by multivariable regression analysis. The seroconversion rates in the post-infection windows of 0-7 days, 10-28 days, and 6-10 weeks were 46%, 84.7%, and 85.3% respectively (n=782). The proportion with a serological response increased with the severity of COVID-19 disease. All participants with severe disease, 89.6% with mild to moderate infection, and 77.3% of asymptomatic participants had IgG antibodies to the RBD antigen. The threshold values in the nasopharyngeal viral RNA RT-PCR in a subset of asymptomatic and symptomatic seroconverters were comparable (p-value: 0.48), with similar results among non-seroconverters (p-value: 0.16) (n=169). This is the first report of longitudinal humoral immune responses to SARS-CoV-2 infection over a period of ten weeks from South Asia. The low seropositivity in asymptomatic participants and differences between assays highlight the importance of contextualizing the understanding of population serosurveys.

show abstract

Section: Discussioncontrasting

confidence: 99%

Longitudinal serology in SARS-CoV-2 infected individuals in India – a prospective cohort study

Thiruvengadam

Chattopadhyay

Mehdi

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The levels of IgG antibodies were higher in symptomatic than asymptomatic groups during the acute phase of infection. Similar data were also reported by other groups ( Shirin et al, 2020 ) ( Long et al, 2020b ). The investigation into the early convalescent phase (8 weeks after discharge from the hospital) showed a decline in IgG level and also a decrease in neutralizing antibodies within 2-3 months.…”

Section: Evaluation Of Antibodies Against Sars-cov-2 In the Sera /Plasma Of Covid-19 Patientssupporting

confidence: 92%

Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing

Mahalingam

Peter

et al. 2021

Heliyon

View full text Add to dashboard Cite

A new pandemic is ongoing in several parts of the world. The agent responsible is the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The symptoms associated with this virus are known as the coronavirus disease-2019 (COVID-19). In this review, we summarize the published data on virus specific antibodies in hospitalized patients with COVID-19 disease, patients recovered from the disease and the individuals who are asymptomatic with SARS-CoV-2 infections. The review highlights the following: i) an adjunct role of antibody tests in the diagnosis of COVID-19 in combination with RT-PCR; ii) status of antibodies from COVID-19 convalescent patients to select donors for plasma therapy; iii) highlights the potential confounding effects of other coronaviruses, measles, mumps and rubella in antibody testing due to homology of certain viral genes; and iv) elaborates the role of antibody testing for conducting surveillance in populations, incidence estimation, contact tracing and epidemiologic studies.

show abstract

“…[12][13][14] However, a recent study performed in Bangladesh reported lower seroconversion rates (45%) among asymptomatic individuals. 15 This raises the possibility that biological responses to SARS COV-2 may vary among different populations.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study

Thiruvengadam

Chattopadhyay

Mehdi

et al. 2021

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Clinical and epidemiological characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now widely available, but there are few data regarding longitudinal serology in large cohorts, particularly those from low-income and middle-income countries. We established an ongoing prospective cohort of 3,840 SARS-CoV-2-positive individuals according to RT-PCR in the Delhi-National Capital Region of India to document clinical and immunological characteristics during illness and convalescence. The immunoglobulin G (IgG) responses to the receptor binding domain (RBD) and nucleocapsid were assessed at 0 to 7 days, 10 to 28 days, and 6 to 10 weeks after infection. The clinical predictors of seroconversion were identified by multivariable regression analysis. The seroconversion rates during the postinfection windows of 0 to 7 days, 10 to 28 days, and 6 to 10 weeks were 46%, 84.7%, and 85.3%, respectively ( N = 743). The proportion with a serological response increased with the severity of coronavirus disease 2019 (COVID-19). All participants with severe disease, 89.6% with mild to moderate infection, and 77.3% of asymptomatic participants had IgG antibodies to the RBD antigen. The threshold values for the nasopharyngeal viral RNA RT-PCR of a subset of asymptomatic and symptomatic seroconverters were comparable ( P = 0.48) to those of nonseroconverters ( P = 0.16) ( N = 169). This is the first report of longitudinal humoral immune responses to SARS-CoV-2 over a period of 10 weeks in South Asia. The low seropositivity of asymptomatic participants and differences between assays highlight the importance of contextualizing the understanding of population serosurveys.

show abstract

Antibody Responses after COVID-19 Infection in Patients Who Are Mildly Symptomatic or Asymptomatic in Bangladesh

Cited by 7 publications

References 0 publications

Longitudinal serology in SARS-CoV-2 infected individuals in India – a prospective cohort study

Longitudinal serology in SARS-CoV-2 infected individuals in India – a prospective cohort study

Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing

Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study

Contact Info

Product

Resources

About